JPRN-UMIN000015077已完成未知
Pharmakocinetics of landiolol in patients with peripheral arterial disease - Pharmakocinetics of landiolol in patients with peripheral arterial disease
Department of Anesthesiology and CCM, Asahikawa Medical University0 个研究点目标入组 8 人开始时间: 2014年9月12日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 8
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients with arrhythmia and patients medicated with alpha-methyldopa, clonidine or beta-blocker
研究者
相似试验
已完成
不适用
Pharmakocinetics of landiolol in patients undergoing cardiac surgeryCardiac diseaseJPRN-UMIN000023699Department of Anesthesiology and CCM, Asahikawa Medical University8
已完成
3 期
Effect of Landiolol as an adjunct to Primary Percutaneous Coronary Intervention in ST-segment Elevation Myocardial InfarctioAcute myocardial infarctionJPRN-UMIN000001872Cardiovascular Division, University of Tsukuba, Graduate School of Comprehensive Human Sciences88
已完成
不适用
The effect of landiolol hydrochloride for primary lung cancer patients with tachyarrhythmia in the perioperative periodPrimary lung cancerJPRN-UMIN000023045Department of Thoracic Surgery, Kitasato University50
进行中（未招募）
不适用
Investigation of the blood levels of selected antibiotics in critically ill patients undergoing dialysisSepsis and acute renal failure (ARF) are pathological entities that commonly co-exist in patients admitted to intensive care. Antibiotic dosing in septic patients with ARF can be complicated and may result in either underdosing, causing treatment failure and antibiotic resistance, or overdosing resulting in drug toxicity. The aim of this study is to collect pharmacokinetic data for evaluating underdosing or overdosing of linezolid and meropenem in patients receiving renal replacement therapy.EUCTR2013-000899-16-DEDepartment of Pharmacy Unversitätsmedizin Mainz
招募中
不适用
PK study of Leuprolide acetate for depot suspension 30 mg with LUPRON DEPOT® (leuprolide acetate for depot suspension) 30 mg in adult male subjects with locally advanced and/or metastatic prostate cancer undergoing initial therapy.CTRI/2022/10/046909American Regent, Inc.